Innovating Works

H2020

Cerrada
HORIZON-CL4-2021-RESILIEN...
HORIZON-CL4-2021-RESILIENCE-01-25: Biomaterials database for Health Applications (CSA)
ExpectedOutcome:Projects are expected to contribute to the following outcomes:
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 23-09-2021.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio..
Esta ayuda financia Proyectos:

ExpectedOutcome:Projects are expected to contribute to the following outcomes:

Create of a database of biomaterials, providing detailed information on the chemical-physical, biological and toxicological properties accessible to wide variety of end-users, for e.g. researchers, companies and clinicians for the purposes of evaluating the biological and clinical usefulness also in the areas beyond their intended primary applications.
Scope:Projects will incorporate data on as many of the material properties as possible, allowing for the development of standardised protocols for the determination and measurement of the efficacy and safety of new biomaterials, taking into account the specificities due to sex, race and age, whether they be single or combination entities. Processing of data should be done in accordance with GDPR provisions.

A label of biocompatibility should be established so as to define the suitability of a biomaterial for eventual use in a Medical Device or Advanced Therapy that the biomaterial becomes a part of, so as to assist companies, especially SMEs, in choosing and facilitating market access for their products.

This d... ver más

ExpectedOutcome:Projects are expected to contribute to the following outcomes:

Create of a database of biomaterials, providing detailed information on the chemical-physical, biological and toxicological properties accessible to wide variety of end-users, for e.g. researchers, companies and clinicians for the purposes of evaluating the biological and clinical usefulness also in the areas beyond their intended primary applications.
Scope:Projects will incorporate data on as many of the material properties as possible, allowing for the development of standardised protocols for the determination and measurement of the efficacy and safety of new biomaterials, taking into account the specificities due to sex, race and age, whether they be single or combination entities. Processing of data should be done in accordance with GDPR provisions.

A label of biocompatibility should be established so as to define the suitability of a biomaterial for eventual use in a Medical Device or Advanced Therapy that the biomaterial becomes a part of, so as to assist companies, especially SMEs, in choosing and facilitating market access for their products.

This database should also contain comparative analyses of the results of biological testing of biomaterials from the scientific literature (and clinical trials, where possible) so as to incorporate data on as many of the material properties as possible, incl. taking into account the specificities defined by sex, race, age. Based upon this, it should be possible to formulate, as necessary, standardised protocols for the determination and measurement of the efficacy and safety of new biomaterials, facilitating as it will, the need to establish high throughput test platforms in the future for biomaterials, that comprise standardised testing protocols for ex vivo, in vivo, pre-clinical and clinical testing.

Proposals must also address all the areas below:

Develop a user-friendly platform for making all relevant data easily and readily accessible for the assessment and decision-making processes in appropriate formats to ensure interoperability. To ensure that the data are processed in accordance with the GDPR provisions;Facilitate extracting, analysing and re-using of the data with advanced data processing technologies e.g. Artificial Intelligence;Provide innovative trainings and manuals for the use of the database and its documentation;Develop a business model for the maintenance of the database demonstrating its sustainability beyond the funding period. A contribution of SSH expertise in the field of economics and marketing would be beneficial for the achievement of this goal. Proposals submitted under this topic should include actions designed to facilitate cooperation with other projects, including; relevant ongoing Open Innovation Test Beds[1], to enhance user involvement, and to ensure the accessibility and reusability of data produced in the course of the project by agreeing on metadata for the description of the materials databases.


[1]Cooperation with projects funded in DT-NMBP-02-2018: OITBs for Safety Testing of Medical Technologies for Health

ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: ExpectedOutcome:Projects are expected to contribute to the following outcomes: ExpectedOutcome:Projects are expected to contribute to the following outcomes:
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Subcontracting costs.
Purchase costs.
Other cost categories.
Indirect costs.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 9:. La tecnología está en su forma final y funciona bajo una amplia gama de condiciones. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
Para el presupuesto subvencionable la intensidad de la ayuda en formato fondo perdido podrá alcanzar como minimo un 100%.
The funding rate for CSA projects is 100 % of the eligible costs for all types of organizations. The funding rate for CSA projects is 100 % of the eligible costs for all types of organizations.
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda no tiene efecto incentivador. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.